Lincoln Pharmaceuticals Files SEBI Certificate for Q4 FY26
Lincoln Pharmaceuticals Limited filed a certificate under SEBI regulations for the quarter ended March 31, 2026. The RTA confirmed processing of dematerialised securities. This is a routine compliance filing.
This is a standard regulatory filing and has no direct impact on the company's operations or financial performance.
The announcement is a routine compliance filing regarding the processing of dematerialised securities and does not contain any material financial or business updates.
Lincoln Pharmaceuticals Limited has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026.
The certificate was received from M/s. MUFG Intime India Private Limited, the company's Registrar & Share Transfer Agent (RTA).
This filing confirms that securities received for dematerialisation during the quarter were processed and confirmed with the depositories, and the certificates were subsequently mutilated and cancelled. The name of the depositories has been substituted in the register of members as the registered owner within the prescribed timelines.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.